COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19, NICE [ES24]

" Whilst no increase in risk of developing COVID-19 or more severe disease was found in the 2 observational studies included, the studies were of poor quality and subject to bias and confounding. Therefore, conclusions cannot be drawn on whether ACEIs or ARBs increase the risk of developing COVID-19 or developing more severe COVID-19. "

Source: Current Awareness Service for Health (CASH) - May 26, 2020 Category: Consumer Health News Source Type: news